Fri Dec 20 11:30:00 UTC 2024: **Eli Lilly Announces $15 Billion Stock Buyback, Signaling Confidence in Future Growth**

**Indianapolis, IN –** Pharmaceutical giant Eli Lilly and Company (LLY) announced a $15 billion stock buyback program, a move interpreted by analysts as a strong vote of confidence in the company’s future. The buyback, to be executed over the next three years, follows a period of significant growth fueled by the success of its weight-loss medications Mounjaro and Zepbound, which have propelled Lilly to become the world’s most valuable pharmaceutical company.

CFO Lucas Montarce stated that while Lilly will continue to invest in new product launches, manufacturing, and R&D, the buyback reflects the company’s strong growth profile and its intention to return capital to shareholders. This suggests that management believes the current stock price undervalues Lilly’s potential.

Analysts point to several factors supporting this optimism. Beyond the continued success of Mounjaro and Zepbound, Lilly is expanding Zepbound’s accessibility through partnerships with telemedicine platforms. Furthermore, GLP-1 receptor agonists like Mounjaro and Zepbound show promise in treating conditions beyond obesity and diabetes, including sleep apnea, arthritis, and Alzheimer’s disease, representing a substantial potential market expansion.

Lilly’s recent FDA approvals for its Alzheimer’s drug, Kisunla, and its eczema treatment, Ebglyss, further bolster its growth prospects. While the Alzheimer’s market is competitive, Kisunla’s injection-based delivery method positions Ebglyss favorably in a crowded eczema market.

Despite the complexity of valuing a company with such diverse and rapidly developing opportunities, Lilly’s PEG ratio of 0.74 suggests undervaluation. While this is not a definitive indicator, combined with the buyback announcement and management’s statements, it points towards a positive outlook for long-term investors. However, potential investors are encouraged to conduct thorough research before making any investment decisions.

Read More